Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protocol for the Diagnosis and Therapy of Intraocular Retinoblastoma
2019-000742-35Phase 2Terminated
- Sponsor
- Italian Association of Pediatric Hematology and Oncology
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan, topotecan, carboplatin, vincristine and etoposide in retinoblastoma (Rb), sponsored by Italian Association of Pediatric Hematology and Oncology. Primary endpoint: ocular event-free survival. Started May 2021; status: terminated.
02
Drugs
melphalantopotecancarboplatinvincristineetoposide
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on 2019-000742-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000742-35.